Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Operating Expenses (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Operating Expenses for 16 consecutive years, with $37.1 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 36.28% to $37.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $104.2 million through Dec 2025, up 17.32% year-over-year, with the annual reading at $105.1 million for FY2025, 17.31% up from the prior year.
  • Operating Expenses for Q4 2025 was $37.1 million at Gyre Therapeutics, up from $23.6 million in the prior quarter.
  • The five-year high for Operating Expenses was $124.0 million in Q4 2022, with the low at -$51.5 million in Q2 2022.
  • Average Operating Expenses over 5 years is $28.1 million, with a median of $22.0 million recorded in 2021.
  • Peak annual rise in Operating Expenses hit 444.79% in 2022, while the deepest fall reached 344.84% in 2022.
  • Over 5 years, Operating Expenses stood at $22.8 million in 2021, then surged by 444.79% to $124.0 million in 2022, then dropped by 4.18% to $118.8 million in 2023, then tumbled by 77.09% to $27.2 million in 2024, then skyrocketed by 36.28% to $37.1 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $37.1 million, $23.6 million, and $24.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.